Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Article uri icon

Overview

publication date

  • July 2, 2018

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Hematopoietic Stem Cell Transplantation
  • Leukemia, Myeloid, Acute
  • Neoplasm Recurrence, Local

Identity

Scopus Document Identifier

  • 85049603735

Digital Object Identifier (DOI)

  • 10.1080/10428194.2018.1468893

PubMed ID

  • 29963936

Additional Document Info

volume

  • 60

issue

  • 1